Supriya Lifescience Ltd (SUPRIYA) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Supriya Lifescience Ltd on NSE and BSE, with an AI summary of each filing.
Enclosed herewith is the announcement under Regulation 30 of SEBI (LODR) Regulations, 2015. Kindly take the same on record.
Others (Uncategorized) · 03 Nov 2026, 2:38 am
Supriya Lifescience Announces Bail Granted to GM Sales & Marketing Under NDPS Act Supriya Lifescience announced that Mr. Sreekant Sreedharan, General Manager – Sales & Marketing, was granted bail by the Sessions Court on 2nd Nov'26 in ongoing judicial proceedings under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985. The bail is subject to court-specified conditions. The company stated that the court order has no material impact on its operations and affirmed it will continue to update stock exchanges on further developments.
Enclosed herewith is the intimation of Results Earnings Call.
Intimation · 06 Nov 2026, 5:00 pm
Supriya Lifescience Schedules Q2 FY27 Earnings Call on 6th Nov'26 Supriya Lifescience Limited will host an earnings conference call on Friday, 6th Nov'26, at 05:00 PM IST to discuss its operational and financial performance for Q2 and H1 FY27 (period ended 30th Sep'26). The management team will be represented by Managing Director Dr. Saloni Wagh, Joint Managing Director Ms. Shivani Wagh, and Chief Financial Officer Mr. Krishna Raghunathan. Dial-in access is available across primary India lines (+91 22 6280 1107 / +91 22 7115 8008) and international toll-free numbers.
SUPRIYA LIFESCIENCE LIMITED has informed the Exchange about Board Meeting to be held on 06-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 06 Nov 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 06 Nov 2026, 5:30 am
Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2026 ,inter alia, to consider and approve In terms of Regulation ....
Intimation · 06 Nov 2026, 5:30 am
Supriya Lifescience Schedules Board Meeting for Q2 and H1 FY27 Results Supriya Lifescience Limited has scheduled its Board of Directors meeting for 6th Nov'26 to consider and approve the unaudited financial results for the quarter and half-year ended 30th Sep'26. Additionally, per the company's Insider Trading Code of Conduct, the trading window for dealing in company securities by designated persons and their immediate relatives has been closed from 1st Oct'26 and will remain shut until 48 hours following the declaration of the financial results on 6th Nov'26.
Enclosed herewith is the announcement under Regulation 30 of SEBI (LODR) Regulations, 2015. Kindly take the same on record.
Others (Uncategorized) · 19 Oct 2026, 4:12 pm
Supriya Lifescience Secures Interim Relief from Supreme Court in Judicial Proceedings Supriya Lifescience Limited announced on 19th Oct'26 that the Hon’ble Supreme Court has admitted its petition and listed the matter for hearing. In an interim order, the Supreme Court directed that no coercive action shall be taken against the company's directors, officers, or officials, subject to specified terms and conditions. The matter remains pending and sub judice, with the company committed to updating exchanges on further material legal developments.
Please find enclosed
Others (Uncategorized) · 13 Oct 2026, 7:39 pm
Supriya Lifescience Assigned 'CRISIL ESG 65' Rating Under 'Strong' Category Supriya Lifescience Limited announced on 13th Oct'26 that CRISIL ESG Ratings & Analytics Limited has voluntarily assigned the company an ESG rating of 'CRISIL ESG 65', placing it in the 'Strong' category. The disclosure was made pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, reflecting the company's established environmental, social, and governance practices.
Enclosed herewith is the announcement under Regulation 30 of SEBI (LODR) Regulations, 2015. Kindly take the same on record.
Others (Uncategorized) · 08 Oct 2026, 10:18 pm
Supriya Lifescience Moves Supreme Court Following High Court Ruling Supriya Lifescience Limited announced that on 8th Oct'26, it filed a petition before the Supreme Court of India in connection with an earlier High Court order dated 23rd Sep'26. The company stated that the matter remains sub judice and under consideration before the apex court, refraining from commenting on the merits or potential outcome. Management will monitor proceedings closely and disclose material updates as received.
Scrutinizer''s Report for 18th Annual General meeting is attached herewith.
Annual General Meeting · 26 Sept 2026, 3:29 am
Outcome of AGM along with Proceedings, Scrutinizer Report and Voting Results is attached herewith.
Annual General Meeting · 26 Sept 2026, 3:25 am
Enclosed herewith is the announcement under Regulation 30 of SEBI (LODR), 2015. Kindly take the same on record.
Others (Uncategorized) · 23 Sept 2026, 5:02 pm
Supriya Lifescience Secures Provisional Release of Ketamine Consignment from Bombay High Court The Hon'ble Bombay High Court, vide order dated 22nd Sep'26, allowed Supriya Lifescience's application for the provisional release of a 200 kg Ketamine Hydrochloride consignment (under Shipping Bill dated 2nd Jun'26). The release is subject to a deposit of ₹72 lakh with the Assistant Commissioner of Customs, Export, ACC, Mumbai-III within one week. The Court clarified that authorities may proceed with ongoing adjudication, criminal proceedings, and procedures under Section 52A of the NDPS Act. The company continues to monitor developments.
Intimation of Analyst/Investor Meeting is enclosed.
Intimation · 21 Sept 2026, 5:11 am
Supriya Lifescience Schedules Virtual Institutional Investor Meeting for September 2026 Supriya Lifescience Limited has scheduled an analyst and institutional investor interaction pursuant to SEBI LODR Regulation 30(6). Company officials are set to host a virtual group meeting on 25th Sep'26, from 11:00 AM to 12:00 Noon. The company confirmed that its investor presentation is accessible via stock exchanges and its official website. The schedule remains subject to changes arising from unforeseen exigencies.
Intimation of Investor/ Analyst Call is enclosed herewith. Kindly take the same on record.
Intimation · 11 Sept 2026, 10:16 pm
Supriya Lifescience Schedules Virtual Institutional Investor Group Meeting Supriya Lifescience Limited announced an interaction with analysts and institutional investors scheduled for 17th Sep'26, from 11:00 AM to 12:00 PM IST. The meeting will be conducted in a virtual group format pursuant to SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The company confirmed that its investor presentation is accessible via stock exchanges and its official website, noting that the schedule remains subject to changes based on operational exigencies.
Enclosed herewith is the copy of Letter dispatched to shareholders whose email ids are not registered. Kindly take the same on record.
Others (Uncategorized) · 02 Sept 2026, 11:52 pm
Supriya Lifescience FY26 Annual Report Dispatch and 18th AGM Schedule Supriya Lifescience scheduled its 18th Annual General Meeting (AGM) for 24th Sep'26 at 3:00 P.M. IST via video conferencing. The company issued weblinks for its FY25-26 Annual Report to shareholders lacking registered emails as of the 21st Aug'26 cut-off date. The FY26 Annual Report and AGM Notice are currently accessible across the company's investor portal, BSE, NSE, and NSDL platforms. Management advises shareholders to update email registries with their respective Depository Participants to streamline future corporate communications.
Enclosed herewith disclosure under Regulation 30.
Others (Uncategorized) · 02 Sept 2026, 11:02 pm
Supriya Lifescience Status Update on Pending Judicial Proceedings Involving GM of Sales Supriya Lifescience reported on 2nd Sep'25 that ongoing judicial proceedings involving its General Manager of Sales & Marketing remain sub judice, awaiting court hearing and adjudication. Currently, there are no new developments or court orders regarding the matter. The company previously communicated the case status during its August earnings call and reiterated its commitment to monitoring the situation. Management confirms it will notify stock exchanges immediately upon receiving any material updates or regulatory orders from the court.
Business Responsibility and Sustainability Report for FY 2025-26
Others (Uncategorized) · 02 Sept 2026, 1:34 am
Notice of 18th AGM of the Company.
Annual General Meeting · 02 Sept 2026, 1:25 am
Annual Report
Others (Uncategorized) · 02 Sept 2026, 1:19 am
Enclosed herewith is the intimation of record date for determining list of members eligible to receive dividend for FY 2025-26.
Dividend · 26 Aug 2026, 10:59 pm
Supriya Lifescience Sets Record Date for FY26 Final Dividend Supriya Lifescience has fixed Fri, Sep 4, '26, as the record date for its FY26 final dividend. The Board recommended a dividend of Re. 1.00 per equity share (face value Rs. 2). This is subject to shareholder approval at the Annual General Meeting, which is scheduled for Thu, Sep 24, '26. If approved, the dividend will be paid within 30 days from the AGM date to eligible shareholders on record.
Earnings Call Transcript of the Earning Call for Unaudited Financial Results for quarter ended June 30, 2026 is enclosed.
Transcript · 18 Aug 2026, 10:07 pm
Audio Link for outcome of Results Earnings Call for United Financial Results for quarter ended June 30, 2026 is enclosed.
Audio / Video · 14 Aug 2026, 10:50 pm
Supriya Lifescience Q1 FY27 Earnings Call Audio Recording Available Supriya Lifescience has released the audio recording of its earnings call held on 14 Aug'26. The call discussed the company's operational and financial performance for the quarter ended 30 Jun'26. The recording is now accessible on the company's investor relations website.
Press Release for Unaudited Financial Results for quarter ended June 30, 2026 is enclosed herewith.
Press Release · 14 Aug 2026, 4:56 am
Supriya Lifescience Q1 FY27: Strong Revenue Growth Offset by Margin Contraction Supriya Lifescience reported strong 30.8% YoY revenue growth to Rs 189.75 crore for Q1 FY27, driven by its export business (81% of sales). However, profitability declined, with EBITDA falling to Rs 47.46 crore from Rs 51.70 crore. The EBITDA margin compressed significantly to 25.0% from 35.6% YoY. Consequently, Profit After Tax (PAT) decreased to Rs 24.04 crore, with the PAT margin shrinking to 12.7% versus 24.0% in Q1 FY26. The Anesthetic segment remained the largest contributor at 48% of revenue.
Investor Presentation for Results Earnings Call for Unaudited Financial Results for quarter ended June 30,2026 is enclosed herewith.
Investor Presentation · 14 Aug 2026, 12:58 am
Supriya Lifescience Q1 FY27: Revenue Up 31% YoY, But Margins Under Pressure Supriya Lifescience reported Q1 FY27 revenue of INR 1,897.5 Mn, a 31% YoY growth, but down 31.4% QoQ. Profitability declined, with EBITDA falling 8% YoY to INR 474.6 Mn and PAT dropping 31% YoY to INR 240.4 Mn. Margin contraction was significant, with EBITDA margin at 25.0% (-1,063 bps YoY) and PAT margin at 12.7% (-1,131 bps YoY). The revenue decline was led by a sharp QoQ drop in Europe's contribution, while Asia's share grew. Exports comprised 81% of Q1FY27 revenue.
Unaudited Financial Results for the quarter ended June 30, 2026 is enclosed.
Financial Result · 14 Aug 2026, 12:18 am
Supriya Lifescience Q1 FY27 Results: Revenue Rises YoY, But Profitability Declines Supriya Lifescience reported Q1 FY27 results with revenue from operations at ₹1,897.47 million, a 30.8% YoY increase but a 31.4% QoQ decline. Total income grew 30.2% YoY to ₹1,923.95 million. However, net profit for the quarter ended 30th Jun'26 fell 31.0% YoY to ₹240.43 million, impacted by a sharp 150% YoY rise in the cost of materials. Consequently, EPS for the quarter dropped to ₹2.99 from ₹4.32 in the prior year's quarter. Sequentially, net profit plummeted 67.6% QoQ from ₹742.29 million.
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its Meeting held ....
Outcome · 14 Aug 2026, 12:05 am
Supriya Lifescience Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Million) ■ Revenue: 1,897 (+30.8% YoY | -31.4% QoQ) ■ EBITDA: 475 (-8.2% YoY | -51.4% QoQ) ■ EBITDA Margin (%): 25.0 (-1063 bps YoY | -1029 bps QoQ) ■ PAT: 240 (-30.9% YoY | -67.6% QoQ) ■ EPS (INR): 2.99 (-30.8% YoY | -67.6% QoQ)